Electronic Supplementary Material (ESI) for Chemical Communications. This journal is © The Royal Society of Chemistry 2017

Supporting Information for

Catalytic Dehydrogenative Dual Functionalization of Ethers: Dealkylation–Oxidation–Bromination Accompanied by C–O Bond via Aerobic Oxidation of Bromide

Katsuhiko Moriyama,*^{†‡}Tsukasa Hamada,[†] Yu Nakamura,[†] and Hideo Togo[†]

Department of Chemistry, Graduate School of Science, Chiba University,[†] 1-33 Yayoi-cho, Inage-ku, Chiba, 263-8522, Japan Molecular Chirality Research Center, Chiba University,[‡] 1-33 Yayoi-cho, Inage-ku, Chiba, 263-8522, Japan

moriyama@faculty.chiba-u.jp

Table of contents

1. General Methods.		S2
2. General Procedure for Catalytic Dehydrogenative Dual Funct 1, Table 1, Table 2, and Table 3).	tionalization of Ethers (1) (Scher	ne
		S2
3. Transformation of 4a into Substituted Furan Derivartives (Sc	heme 2).	13
4. Mechanistic Studies for Catalytic Dehydrogenative Dual Fun	ctionalization of Ethers (1).	18
5. ¹ H and ¹³ C NMR Spectra of Materials	S	21

1. General Methods. ¹H NMR spectra were measured on a JEOL ECS-400 (400 MHz) spectrometer at ambient temperature. Data were recorded as follows: chemical shift in ppm from internal tetramethylsilane on the δ scale, multiplicity (s = singlet; d = doublet; t = triplet; q = quartet; sep = septet; m = multiplet; br = broad), coupling constant (Hz), integration, and assignment. ¹³C NMR spectra were measured on a JEOL ECS-400 (100 MHz) spectrometer. Chemical shifts were recorded in ppm from the solvent resonance employed as the internal standard (deuterochloroform at 77.0 ppm). High-resolution mass spectra were recorded by Thermo Fisher Scientific Exactive Orbitrap mass spectrometers. Infrared (IR) spectra were recorded on a JASCO FT/IR 4100 spectrometer. Single crystal X-ray diffraction data were collected at 173K on a Bruker SMART APEX II CCD diffractometer with Mo K α ($\lambda = 0.71073$) radiation and graphite monochromator. For thin-layer chromatography (TLC) analysis throughout this work, Merck precoated TLC plates (silica gel 60GF254 0.25 mm) were used. The products were purified by neutral column chromatography on silica gel (Kanto Chemical Co., Inc. silica gel 60N, Prod. No. 37560-84; Merck silica gel 60, Prod. No. 1.09385.9929). Visualization was accomplished by UV light (254 nm), anisaldehyde, KMnO₄, and phosphomolybdic acid. In experiments that required dry solvents were distilled in prior to use.

2. General Procedure for Catalytic Dehydrogenative Dual Functionalization of Ethers (1) (Scheme 1, Table 1, Table 2, and Table 3).

To a solution of **1a** (113.2 mg, 0.50 mmol), NaNO₂ (3.5 mg, 0.050 mmol), and 4-nitrobenzenesulfonamide (10.1 mg, 0.050 mmol) in MeCN (3.0 mL) was added 48% aq. HBr (169.7 μ L, 1.5 mmol) at 0 °C under oxygen atmosphere (1 atm). After stirred at the same temperature for 30 min, the reaction mixture was stirred at 60 °C for 24 h. Saturated Na₂SO₃ aqueous solution (10 mL) was added to the mixture, and the product was extracted with AcOEt (20 mL × 3). The organic phase was washed with brine (20 mL) and dried over Na₂SO₄. The organic phase concentrated under reduced pressure, and the crude products was purified by column chromatography (eluent: hexane/AcOEt = 30/1) to give the desired products **2a** (99.5 mg, 93 % yield).





Entry	NaNO ₂	Additive	Solvent	Temp.	Yield
	(mol%)			(°C)	(%)
1	20	-	CHCl ₃	50	$10(70)^{a}$
2	20	-	AcOEt	50	$64(28)^{b}$
3	20	-	MeCN	50	$55 (42)^c$
4	10	-	MeCN	60	$82(11)^{c}$
5	10	PhCONH ₂	MeCN	60	$71(15)^d$
6	10	<i>p</i> -NO ₂ C ₆ H ₄ CONH ₂	MeCN	60	$87(5)^{c}$
7	10	<i>p</i> -CF ₃ C ₆ H ₄ CONH ₂	MeCN	60	87
8	10	3,4-(NO ₂) ₂ C ₆ H ₃ CONH ₂	MeCN	60	83
9	10	C ₆ F ₅ CONH ₂	MeCN	60	$51(24)^d$
10	10	<i>p</i> -NO ₂ C ₆ H ₄ SO ₂ NH ₂	MeCN	60	93
11	10	<i>p</i> -NO ₂ C ₆ H ₄ SO ₂ NHMe	MeCN	60	$63(11)^{c}$
12^{e}	10	<i>p</i> -NO ₂ C ₆ H ₄ SO ₂ NH ₂	MeCN	60	$68 (4)^c$
13	-	$p-NO_2C_6H_4SO_2NH_2$	MeCN	60	0
14^{f}	10	<i>p</i> -NO ₂ C ₆ H ₄ SO ₂ NH ₂	MeCN	60	0

^{*a*}Number in brackets indicates yield of (α -bromopropyl)benzene. ^{*b*}Number in brackets indicates recovery of **1a**. ^{*c*}Number in brackets indicates yield of propiophenone. ^{*d*}Number in brackets indicates yield of α, α -dibromopropiophenone. ^{*e*}HBr (2.0 equiv.) was used. ^{*f*}The reaction was carried out in air.



2-Bromo-1-phenylpropan-1-one (2a): ¹H NMR (400 MHz, CDCl₃) δ 1.91 (d, J = 6.9 Hz, 3H), 5.30 (q, J = 6.9 Hz, 1H), 7.45-7.52 (m, 2H), 7.56-7.63 (m, 1H), 8.00-8.06 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 20.1, 41.4, 128.7 (2C), 128.9 (2C), 133.7, 134.0, 193.3. IR (neat) 2978, 1685, 1345, 1236, 1160 cm⁻¹. MS (ESI) calcd for C₉H₁₀BrO [M+H]⁺ 212.9910, found 212.9912.



2-Bromo-1-(*p*-tolyl)ethan-1-one (2b): ¹H NMR (400 MHz, CDCl₃) δ 2.43 (s, 3H), 4.43 (s, 2H), 7.26-7.32 (m, 2H), 7.85-7.91 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 21.7, 31.0, 129.0 (2C), 129.5 (2C), 131.4, 145.0, 190.9. IR (neat) 2952, 1690, 1391, 1285, 1180 cm⁻¹.



2-Bromo-1-(4-chlorophenyl)ethan-1-one (2c): ¹H NMR (400 MHz, CDCl₃) δ 4.42 (s, 2H), 7.44-7.50 (m, 2H), 7.91-7.96 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 30.4, 129.2 (2C), 130.3 (2C), 132.2, 140.5, 190.2. IR (neat) 2954, 1693, 1400, 1283, 1197 cm⁻¹.



2-Bromo-1-(4-bromophenyl)ethan-1-one (2d): ¹H NMR (400 MHz, CDCl₃) δ 4.42 (s, 2H), 7.60-7.65 (m, 2H), 7.82-7.87 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 30.5, 129.2, 130.3 (2C), 132.1 (2C), 132.5, 190.3. IR (neat) 2952, 1693, 1395, 1284, 1194 cm⁻¹.



2-Bromo-1-(4-(trifluoromethyl)phenyl)ethan-1-one (2e): ¹H NMR (400 MHz, CDCl₃) δ 4.46 (s, 2H), 7.77 (d, J = 8.2 Hz, 2H), 8.10 (d, J = 8.2 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 30.3, 123.4 (q, $J_{C-F} = 274.0$ Hz), 125.9 (q, $J_{C-F} = 3.8$ Hz, 2C), 129.3 (2C), 135.1 (q, $J_{C-F} = 32.6$ Hz), 136.6, 190.4. ¹⁹F NMR (471 MHz, CDCl₃) δ -63.2. IR (neat) 2947, 1700, 1411, 1326, 1110 cm⁻¹. MS (APPI) calcd for C₉H₇BrF₃O [M+H]⁺ 266.9627, found 266.9629.



2-Bromo-1-(4-(phenylsulfonyl)phenyl)ethan-1-one (2f): ¹H NMR (400 MHz, CDCl₃) δ 4.44 (s, 2H), 7.51-7.58 (m, 2H), 7.59-7.65 (m, 1H), 7.94-7.99 (m, 2H), 8.02-8.07 (m, 2H), 8.07-8.11 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 30.3, 127.8 (2C), 128.0 (2C), 129.5 (2C), 129.7 (2C), 133.8, 137.2, 140.4, 146.0, 190.1. IR (neat) 2953, 1708, 1399, 1298, 1155 cm⁻¹. MS (APCI) calcd for C₁₄H₁₂BrO₃S [M+H]⁺ 338.9685, found 338.9687.



4-(2-Bromoacetyl)benzonitrile (2g): ¹H NMR (400 MHz, CDCl₃) δ 4.45 (s, 2H), 7.79-7.85 (m, 2H), 8.07-8.12 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 30.0, 117.1, 117.6, 129.4 (2C), 132.6 (2C), 136.8, 190.1. IR (neat) 2940, 2224, 1706, 1387, 1272, 1193 cm⁻¹. MS (APCI) calcd for C₉H₇BrNO [M+H]⁺ 223.9706, found 223.9710.



2-Bromo-1-(*m***-tolyl)ethan-1-one (2h (X = H)):** ¹H NMR (400 MHz, CDCl₃) δ 2.42 (s, 3H), 4.45 (s, 2H), 7.32-7.44 (m, 2H), 7.73-7.44 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 21.3, 31.1, 126.1, 128.6, 129.3, 133.9, 134.7, 138.7, 191.4. IR (neat) 2945, 1679, 1392, 1283, 1153 cm⁻¹. MS (APCI) calcd for C₉H₁₀BrO [M+H]⁺ 212.9910, found 212.9908.



2-Bromo-1-(4-bromo-3-methylphenyl)ethan-1-one (2h (X = Br)): ¹H NMR (400 MHz, CDCl₃) δ 2.48 (s, 3H), 4.41 (s, 2H), 7.62-7.69 (m, 2H), 7.83-7.86 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 23.0, 30.5, 127.6, 130.9, 131.7, 132.87, 132.95, 138.9, 190.7. IR (neat) 2947, 1693, 1385, 1272, 1177 cm⁻¹. MS (APCI) calcd for C₉H₉Br₂O [M+H]⁺ 290.0915, found 290.9015.



2-Bromo-1-(3-chlorophenyl)ethan-1-one (2i): ¹H NMR (400 MHz, CDCl₃) δ 4.43 (s, 2H), 7.45 (t, J = 8.0 Hz, 1H), 7.56-7.62 (m, 1H), 7.86 (d, J = 8.0 Hz, 1H), 7.96 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 30.5, 127.0, 128.9, 130.2, 133.9, 135.2, 135.4, 190.1. IR (neat) 2941, 1684, 1420, 1261, 1192 cm⁻¹. MS (APCI) calcd for C₈H₇BrClO [M+H]⁺ 232.9363, found 232.9367.



2-Bromo-1-(*o*-tolyl)ethan-1-one (2j): ¹H NMR (400 MHz, CDCl₃) δ 2.52 (s, 3H), 4.42 (s, 2H), 7.25-7.32 (m, 2H), 7.42 (td, J = 7.6, 1.2 Hz, 1H), 7.63-7.69 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 21.4, 33.7, 125.8, 129.0, 132.30, 132.34, 134.3, 139.7, 194.1. IR (neat) 2965, 1680, 1383, 1260, 1186 cm⁻¹. MS (APCI) calcd for C₉H₁₀BrO [M+H]⁺ 212.9910, found 212.9911.



2-Bromo-3,4-dihydronaphthalen-1(*2H*)-one (2k): ¹H NMR (400 MHz, CDCl₃) δ 2.41-2.58 (m, 2H), 2.92 (dt, J = 17.3, 4.5 Hz, 1H), 3.31 (ddd, J = 17.3, 10.0, 4.8 Hz, 1H), 4.73 (dd, J = 4.8, 4.1 Hz, 1H), 7.28 (d, J = 7.8 Hz, 1H), 7.34 (t, J = 7.8 Hz, 1H), 7.52 (td, J = 7.8, 1.4 Hz, 1H), 8.08 (dd, J = 7.8, 1.4 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 26.0, 31.8, 50.4, 127.0, 128.6, 128.7, 129.8, 134.1, 142.9, 190.5. IR (neat) 2946, 1680, 1454, 1303, 1195 cm⁻¹. MS (APCI) calcd for C₁₀H₁₀BrO [M+H]⁺ 224.9910, found 224.9909.



2-Bromo-2-methyl-1-phenylpropan-1-one (2l): ¹H NMR (400 MHz, CDCl₃) δ 2.04 (s, 6H), 7.40-7.47 (m, 2H), 7.50-7.57 (m, 1H), 8.11-8.18 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 31.5 (2C), 60.3, 128.1 (2C), 130.1 (2C), 132.4, 134.8, 196.9. IR (neat) 2928, 1674, 1387, 1268, 1167 cm⁻¹.



(1-Bromocyclohexyl)(phenyl)methanone (2m): ¹H NMR (400 MHz, CDCl₃) δ 1.32-1.44 (m, 1H), 1.46-1.64 (m, 3H), 1.72-1.87 (m, 2H), 2.11-2.25 (m, 2H), 2.27-2.38 (m, 2H), 7.38-7.45 (m, 2H), 7.49-7.55 (m, 1H), 8.04-8.10 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 23.5 (2C), 24.9, 38.2 (2C), 67.9, 128.1 (2C), 129.8 (2C), 132.0, 135.8, 197.5. IR (neat) 2934, 1675, 1446, 1245, 1181 cm⁻¹. MS (APCI) calcd for C₁₃H₁₆BrO [M+H]⁺ 267.0379, found 267.0377.



2-Bromo-1-phenylpentan-1-one (2n): ¹H NMR (400 MHz, CDCl₃) δ 0.99 (t, *J* = 7.5 Hz, 3H), 1.37-1.51 (m, 1H), 1.51-1.65 (m, 1H), 2.06-2.25 (m, 2H), 5.16 (dd, *J* = 8.0, 6.6 Hz, 1H), 7.45-7.52 (m, 2H), 7.60 (tt, *J* = 7.6, 1.4 Hz, 1H), 7.99-8.05 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 13.6, 20.8, 35.4, 47.0, 128.75 (2C), 128.81 (2C), 133.6, 134.5, 193.3. IR (neat) 2961, 1684, 1448, 1272, 1210 cm⁻¹. MS (ESI) calcd for C₁₁H₁₄BrO [M+H]⁺ 241.0223, found 241.0225.



2-Bromocyclododecan-1-one (20): ¹H NMR (400 MHz, CDCl₃) δ 1.13-1.46 (m, 14H), 1.51-1.65 (m, 1H), 1.82-2.06 (m, 2H), 2.24-2.38 (m, 1H), 2.71 (ddd, J = 16.8, 11.2, 3.6 Hz, 1H), 2.81 (ddd, J = 16.8, 6.4, 3.6 Hz, 1H), 4.39 (dd, J = 11.8, 3.6 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 22.1, 22.4, 23.7 (2C), 23.9, 24.0, 25.1, 25.3, 33.5, 35.2, 51.6, 205.6. IR (neat) 2929, 1711, 1469, 1362, 1243, 1140 cm⁻¹. MS (APCI) calcd for C₁₂H₂₂BrO [M+H]⁺ 261.0849, found 261.0847.



2-Bromocyclooctan-1-one (2p): ¹H NMR (400 MHz, CDCl₃) δ 1.10-1.24 (m, 1H), 1.34-1.47 (m, 1H), 1.50-1.63 (m, 2H), 1.63-1.84 (m, 3H), 1.88-1.99 (m, 1H), 2.26-2.46 (m, 3H), 2.88 (td, J = 12.4, 4.0 Hz, 1H), 4.28 (dd, J = 11.2, 4.0 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 23.9, 25.3, 26.5, 28.7, 32.6, 36.1, 54.3, 208.7. IR (neat) 2929, 1702, 1466, 1327, 1213, 1147 cm⁻¹. MS (APCI) calcd for C₈H₁₄BrO [M+H]⁺ 205.0223, found 205.0223.



4-Bromononan-5-one (2q): ¹H NMR (400 MHz, CDCl₃) δ 0.94 (dt, J = 10.5, 7.5 Hz, 6H), 1.27-1.42 (m, 3H), 1.42-1.59 (m, 1H), 1.54-1.65 (m, 2H), 1.85-2.03 (m, 2H), 2.58-2.77 (m, 2H), 4.26 (dd, J = 8.2, 6.6 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 13.4, 13.8, 20.6, 22.2, 26.0, 35.4, 38.7, 53.5, 204.5. IR (neat) 2959, 1714, 1464, 1380, 1259, 1042 cm⁻¹. MS (APCI) calcd for C₉H₁₈BrO [M+H]⁺ 221.0536, found 221.0535.



3-Bromooctan-2-one (2r–2°): ¹H NMR (400 MHz, CDCl₃) δ 0.89 (t, J = 6.8 Hz, 3H), 1.24-1.40 (m, 5H), 1.41-1.54 (m, 1H), 1.85-2.06 (m, 2H), 2.36 (s, 3H), 4.23 (dd, J = 8.2, 6.6 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 13.9, 22.3, 26.0, 26.9, 31.1, 33.5, 54.4, 202.2. IR (neat) 2929, 1718, 1465, 1358, 1232, 1147 cm⁻¹. MS (APCI) calcd for C₈H₁₆BrO [M+H]⁺ 207.0379, found 207.0380.



1-Bromooctan-2-one (2r–1°): ¹H NMR (400 MHz, CDCl₃) δ 0.89 (t, J = 7.0 Hz, 3H), 1.23-1.36 (m, 6H), 1.57-1.66 (m, 2H), 2.65 (t, J = 7.5 Hz, 2H), 3.89 (s, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 14.0, 22.4, 23.8, 28.7, 31.5, 34.3, 39.8, 202.2. IR (neat) 2928, 1715, 1464, 1377, 1174 cm⁻¹. MS (APCI) calcd for C₈H₁₆BrO [M+H]⁺ 207.0379, found 207.0385.



2-Bromo-1-cyclohexylethan-1-one (2s–1°): ¹H NMR (400 MHz, CDCl₃) δ 1.14-1.46 (m, 5H), 1.64-1.73 (m, 1H), 1.75-1.84 (m, 2H), 1.84-1.93 (m, 2H), 2.71 (tt, *J* = 11.2, 3.4 Hz, 1H), 3.97 (s, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 25.4 (2C), 25.6, 28.7 (2C), 33.4, 48.0, 204.6. IR (neat) 2929, 1708, 1448, 1394, 1246, 1144 cm⁻¹. MS (APCI) calcd for C₈H₁₄BrO [M+H]⁺ 205.0223, found 205.0228.



1-(1-Bromocyclohexyl)ethan-1-one (2s-3°): ¹H NMR (400 MHz, CDCl₃) δ 1.27-1.41 (m, 1H), 1.52-1.66 (m, 3H), 1.70-1.85 (m, 2H), 1.88-2.06 (m, 2H), 2.09-2.21 (m, 2H), 2.41 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 23.2, 24.1, 24.8 (2C), 36.4 (2C), 71.3, 202.9. IR (neat) 2935, 1709, 1446, 1354, 1227, 1189 cm⁻¹. MS (APCI) calcd for C₈H₁₄BrO [M+H]⁺ 205.0223, found 205.0222.



1-Bromo-1-phenylhexan-2-one (2t): ¹H NMR (400 MHz, CDCl₃) δ 0.84 (t, J = 7.5 Hz, 3H), 1.19-1.31 (m, 2H), 1.50-1.60 (m, 3H), 2.55 (dt, J = 17.4, 7.3 Hz, 1H), 2.61 (dt, J = 17.4, 7.6 Hz, 1H), 7.30-7.39 (m, 3H), 7.39-7.45 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 13.7, 22.0, 26.1, 38.8, 55.7, 128.8 (2C), 129.0 (2C), 129.1, 135.3, 201.6. IR (neat) 2957, 1724, 1454, 1363, 1259, 1122 cm⁻¹. MS (APCI) calcd for C₁₂H₁₆BrO [M+H]⁺ 255.0379, found 255.0380.



(8*R*,9*S*,10*S*,13*R*,14*S*,17*R*)-2-Bromo-10,13-dimethyl-17-((*R*)-5-methylhexan-2-yl)hexadecahydr o-3*H*-cyclopenta[*a*]phenanthren-3-one (2u (X = H)): ¹H NMR (400 MHz, CDCl₃) δ 0.67 (s, 3H), 0.72-0.82 (m, 1H), 0.860 (d, *J* = 6.6 Hz, 3H), 0.863 (d, *J* = 6.6 Hz, 3H), 0.90 (d, *J* = 6.8 Hz, 3H), 0.93-1.19 (m, 9H), 1.08 (s, 3H), 1.19-1.45 (m, 8H), 1.45-1.66 (m, 4H), 1.66-1.75 (m, 1H), 1.75-1.90 (m, 2H), 2.00 (dt, *J* = 13.2, 3.2 Hz, 1H), 2.34-2.48 (m, 2H), 2.63 (dd, *J* = 13.2, 6.4 Hz, 1H), 4.76 (dd, *J* = 13.6, 6.4 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 12.0, 12.1, 18.6, 21.5, 22.5, 22.8, 23.7, 24.1, 27.9, 28.1, 28.3, 31.4, 34.8, 35.7, 36.0, 38.9, 39.4, 39.6, 42.5, 43.9, 47.4, 51.6, 53.5, 54.6, 56.0, 56.1, 201.2. IR (neat) 2927, 1720, 1442, 1378, 1186 cm⁻¹. MS (APCI) calcd for C₂₇H₄₆BrO [M+H]⁺ 465. 2727, found 465.2720.



(8*R*,9*S*,10*S*,13*R*,14*S*,17*R*)-2,2-Dibromo-10,13-dimethyl-17-((*R*)-5-methylhexan-2-yl)hexadecah ydro-3*H*-cyclopenta[*a*]phenanthren-3-one (2u (X = Br)): ¹H NMR (400 MHz, CDCl₃) δ 0.67 (s, 3H), 0.63-0.73 (m, 1H), 0.861 (d, *J* = 6.6 Hz, 3H), 0.865 (d, *J* = 6.6 Hz, 3H), 0.90 (d, *J* = 6.8 Hz, 3H), 0.92-1.18 (m, 8H), 1.24 (s, 3H), 1.18-1.61 (m, 12H), 1.61-1.74 (m, 2H), 1.76-1.89 (m, 1H), 1.95-2.04 (m, 1H), 2.33 (dd, *J* = 15.3, 3.2 Hz, 1H), 2.73 (d, *J* = 15.8 Hz, 1H), 3.07 (t, *J* = 14.9 Hz, 1H), 3.24 (d, *J* = 15.8 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 12.1, 13.3, 18.6, 21.4, 22.5, 22.8, 23.8, 24.1, 27.98, 28.07, 28.13, 31.3, 34.3, 35.7, 36.1, 38.8, 39.1, 39.5, 39.7, 42.6, 46.5, 55.3, 55.9, 56.1, 62.5, 66.3, 195.1. IR (neat) 2932, 1731, 1444, 1384, 1169 cm⁻¹. MS (APCI) calcd for $C_{27}H_{45}Br_2O$ [M+H]⁺ 543.1832, found 543.1834.



3,3-Bibromo-2-phenyltetrahydrofuran-2-ol (4a): ¹H NMR (400 MHz, CDCl₃) δ 3.07 (ddd, J = 13.8, 7.1, 2.0 Hz, 1H), 3.25 (s, 1H), 3.46 (dt, J = 13.8, 9.5 Hz, 1H), 4.12 (ddd, J = 9.5, 8.3, 2.0 Hz, 1H), 4.29 (ddd, J = 9.5, 8.3, 7.1 Hz, 1H), 7.38-7.44 (m, 3H), 7.79-7.86 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 47.0, 65.1, 67.5, 105.7, 127.5 (2C), 127.6 (2C), 129.4, 138.2. IR (neat) 3368, 1440, 1398, 1257, 1022 cm⁻¹. MS (ESI) calcd for C₁₀H₁₀Br₂NaO₂ [M+Na]⁺ 342.8940, found

342.8954.

Crystal data of 4a: Crystallographic data (excluding structure factors) for the structure reported in this paper have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication no. CCDC-1531429. Copies of the data can be obtained free of charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [Fax: int. code + 44(1223)336-033; E-mail: deposit@ccdc.cam.ac.uk].



Figure S1. ORTEP drawing of 4a.

Formula	$C_{10}H_{10}Br_2O_2$		
Formula Weight	322.00		
Temperature	173 K		
Wavelength	0.71073 Å		
Crystal System	Monoclinic		
Space Group	P 1 21/c 1		
Unit Cell Dimensions	$a = 20.362(2)$ Å $\alpha = 90.00$ °		
	$b = 6.3138(7)$ Å $\beta = 95.2864(16)$ °		
	$c = 16.3787(18)$ Å $\gamma = 90.00$ °		
Volume	2096.7(4) Å ³		
Z Value	8		
Calculated Density	2.040 g cm^{-3}		
Absorption coeficiente	7.702 mm^{-1}		
F(000)	1248		
Crystal size	0.20×0.20×0.10 mm ³		
Theta Range for Data Collection	2.4977-27.2970		
Index Ranges	$-23 \le h \le 26, -6 \le k \le 8, -16 \le l \le 21$		
Reflections Collected	4737		
Independent Reflections	4737 [R(int) = 0.0000]		
Completeness to Theta = 27.462°	98.7%		
Refinement Method	Full-matrix least-squares on F ²		

Data/ Restraints/ Parameters Goodness-of-Fit onF² Final R Indices [I>2sigma(I)] R Indices (All Data) Largest Diff. Peak and Hole 4737/0/2551.040 $R_1 = 0.0357$ and $wR_2 = 0.0572$ $R_1 = 0.0642$ and $wR_2 = 0.0635$ 0.491 and -0.554 e⁻/Å³

3,3-Dibromo-2-(*p*-tolyl)tetrahydrofuran-2-ol (4b): ¹H NMR (400 MHz, CDCl₃) δ 2.39 (s, 3H), 3.06 (ddd, *J* = 13.6, 7.0, 1.8 Hz, 1H), 3.21 (s, 1H), 3.45 (dt, *J* = 13.6, 9.4 Hz, 1H), 4.11 (ddd, *J* = 9.4, 8.2, 1.8 Hz, 1H), 4.27 (ddd, *J* = 9.4, 8.2, 7.0 Hz, 1H), 7.17-7.23 (m, 2H), 7.66-7.72 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 21.3, 46.9, 65.0, 67.9, 105.8, 127.4 (2C), 128.3 (2C), 135.2, 139.3. IR (neat) 3361, 1441, 1393, 1266, 1025 cm⁻¹. MS (ESI) calcd for C₁₁H₁₃Br₂O₂ [M+H]⁺ 334.9277, found 334.9276.



3,3-Dibromo-2-(4-chlorophenyl)tetrahydrofuran-2-ol (4c): ¹H NMR (400 MHz, CDCl₃) δ 3.04 (ddd, J = 13.6, 7.0 Hz, 1H), 3.41 (dt, J = 13.6, 9.5 Hz, 1H), 3.53 (s, 1H), 3.98-4.06 (m, 1H), 4.20-4.29 (m, 1H), 7.31-7.38 (m, 2H), 7.68-7.74 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 46.8, 65.2, 67.0, 105.4, 127.7 (2C), 129.0 (2C), 135.5, 136.6. IR (neat) 3384, 1439, 1343, 1251, 1012 cm⁻¹. MS (APCI) calcd for C₁₀H₁₀Br₂ClO₂ [M+H]⁺ 354.8731, found 354.8727.



3,3-Dibromo-2-(4-bromophenyl)tetrahydrofuran-2-ol (4d): ¹H NMR (400 MHz, CDCl₃) δ 3.04 (ddd, J = 13.6, 6.8, 1.7 Hz, 1H), 3.38 (s, 1H), 3.42 (dt, J = 13.6, 9.4 Hz, 1H), 4.02-4.10 (m, 1H), 4.22-4.31 (m, 1H), 7.48-7.54 (m, 2H), 7.63-7.69 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 46.8, 65.3, 67.0, 105.4, 123.9, 129.3 (2C), 130.7 (2C), 137.1. IR (neat) 3337, 1441, 1392, 1262, 1009 cm⁻¹. MS (APCI) calcd for C₁₀H₁₀Br₃O₂ [M+H]⁺ 398.8225, found 398.8222.



3,3-Dibromo-2-(4-(trifluoromethyl)phenyl)tetrahydrofuran-2-ol (4e): ¹H NMR (400 MHz, CDCl₃) δ 3.07 (ddd, J = 14.0, 7.2, 2.0 Hz, 1H), 3.44 (s, 1H), 3.44 (dt, J = 14.0, 9.6 Hz, 1H), 4.03-4.12 (m, 1H), 4.29 (ddd, J = 9.6, 8.6, 7.2 Hz, 1H), 7.64 (d, J = 8.4 Hz, 2H), 7.91 (d, J = 8.4 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 46.8, 65.5, 66.4, 105.3, 123.9 (q, $J_{C-F} = 276.5$ Hz), 124.5 (q, $J_{C-F} = 3.8$ Hz, 2C), 128.1 (2C), 131.4 (q, $J_{C-F} = 33.4$ Hz), 141.8. ¹⁹F NMR (471 MHz, CDCl₃) δ -62.6. IR (neat) 3341, 1406, 1325, 1116, 1056, 1012 cm⁻¹. MS (APCI) calcd for C₁₁H₁₀Br₂F₃O₂ [M+H]⁺ 388.8994, found 388.8989.



3,3-Dibromo-2-(naphthalen-2-yl)tetrahydrofuran-2-ol (4f): ¹H NMR (400 MHz, CDCl₃) δ 3.02-3.11 (m, 1H), 3.46 (dt, *J* = 13.8, 9.4 Hz, 1H), 3.64 (s, 1H), 4.05-4.13 (m, 1H), 4.24-4.35 (m, 1H), 7.45-7.54 (m, 2H), 7.76-7.94 (m, 4H), 8.26 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 47.0, 65.2, 67.6, 105.8, 124.9, 126.2, 126.7, 127.1, 127.2, 127.6, 128.7, 132.3, 133.6, 135.6. IR (neat) 3243, 1436, 1356, 1223, 1190 cm⁻¹. MS (APCI) calcd for C₁₄H₁₃Br₂O₂ [M+H]⁺ 370.9277, found 370.9275.



3,3-Dibromo-2-(3-chlorophenyl)tetrahydrofuran-2-ol (4g): ¹H NMR (400 MHz, CDCl₃) δ 3.07 (ddd, J = 13.5, 6.8, 1.8 Hz, 1H), 3.18 (s, 1H), 3.45 (dt, J = 13.5, 9.4 Hz, 1H), 4.10-4.19 (m, 1H), 4.30 (ddd, J = 9.4, 8.2, 6.8 Hz, 1H), 7.30-7.36 (m, 1H), 7.36-7.42 (m, 1H), 7.71 (dt, J = 7.5, 1.4 Hz, 1H), 7.80 (t, J = 1.8 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 46.9, 65.4, 66.7, 105.1, 125.7, 127.9, 128.9, 129.5, 133.6, 140.1. IR (neat) 3370, 1436, 1376, 1247, 1044 cm⁻¹. MS (APCI) calcd for C₁₀H₁₀Br₂ClO₂ [M+H]⁺ 354.8731, found 354.8725.



3,3-Dibromo-2-(2-fluorophenyl)tetrahydrofuran-2-ol (4h): ¹H NMR (400 MHz, CDCl₃) δ 3.05 (ddd, J = 13.8, 6.8, 2.1 Hz, 1H), 3.44 (dt, J = 13.8, 9.4 Hz, 1H), 4.17 (d, J = 9.8 Hz, 1H), 4.22 (td, J = 8.2, 2.1 Hz, 1H), 4.32 (ddd, J = 9.4, 8.2, 6.8 Hz, 1H), 7.07-7.22 (m, 2H), 7.34-7.43 (m, 1H), 7.74 (td, J = 8.2, 1.8 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 46.7, 65.9, 68.3, 106.4 (d, $J_{C-F} = 3.8$ Hz), 116.3 (d, $J_{C-F} = 24.0$ Hz), 123.3 (d, $J_{C-F} = 2.9$ Hz), 124.3 (d, $J_{C-F} = 9.6$ Hz), 131.3 (d, $J_{C-F} = 5.8$ Hz), 131.4, 160.2 (d, $J_{C-F} = 248.1$ Hz). ¹⁹F NMR (471 MHz, CDCl₃) δ –109.9. IR (neat) 3360, 1445, 1360, 1279, 1027 cm⁻¹. MS (APCI) calcd for C₁₀H₁₀Br₂FO₂ [M+H]⁺ 338.9026, found 338.9018.



3,3-Dibromo-2-(3,5-difluorophenyl)tetrahydrofuran-2-ol (4i): ¹H NMR (400 MHz, CDCl₃) δ 3.06 (ddd, J = 14.0, 6.8, 1.6 Hz, 1H), 3.41 (s, 1H), 3.43 (dt, J = 14.0, 9.6 Hz, 1H), 4.07-4.15 (m, 1H), 4.29 (ddd, J = 9.6, 8.4, 6.8 Hz, 1H), 6.85 (tt, J = 9.0, 2.4 Hz, 1H), 7.29-7.37 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 46.7, 65.6, 66.0, 104.82 (t, $J_{C-F} = 25.8$ Hz), 104.83 (t, $J_{C-F} = 2.9$ Hz), 111.0 (dd, $J_{C-F} = 20.0$, 7.6 Hz, 2C), 141.9 (t, $J_{C-F} = 9.1$ Hz), 163.4 (dd, $J_{C-F} = 251.8$, 12.4 Hz, 2C). ¹⁹F NMR (471 MHz, CDCl₃) δ –109.4. IR (neat) 3338, 1600, 1436, 1326, 1114, 1051 cm⁻¹. MS (DART) calcd for C₁₀H₉Br₂F₂O₂ [M+H]⁺ 356.8932, found 356.8935.



3,3-Dibromo-2-(3,5-dichlorophenyl)tetrahydrofuran-2-ol (4j): ¹H NMR (400 MHz, CDCl₃) δ 3.06 (ddd, J = 13.6, 6.8, 1.6 Hz, 1H), 3.42 (td, J = 13.6, 9.6 Hz, 1H), 3.48 (s, 1H), 4.07-4.15 (m, 1H), 4.24-4.33 (m, 1H), 7.39 (t, J = 2.0 Hz, 1H), 7.66 (d, J = 2.0 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 46.7, 65.6, 66.0, 104.7, 126.3 (2C), 129.5 (2C), 134.2, 141.3. IR (neat) 3363, 1567, 1417, 1363, 1254, 1060 cm⁻¹. MS (APCI) calcd for C₁₀H₉Br₂Cl₂O₂ [M+H]⁺ 388.8341, found 388.8337.



3,3-Dibromo-2-(3-chloro-4-methylphenyl)tetrahydrofuran-2-ol (4k): ¹H NMR (400 MHz, CDCl₃) δ 2.40 (s, 3H), 3.04 (ddd, J = 13.8, 6.8, 2.0 Hz, 1H), 3.41 (dt, J = 13.8, 9.6 Hz, 1H), 3.55 (s, 1H), 4.00-4.10 (m, 1H), 4.20-4.31 (m, 1H), 7.23 (d, J = 8.4 Hz, 1H), 7.56 (dd, J = 8.4, 2.0 Hz, 1H), 7.74 (d, J = 2.0 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 19.9, 46.8, 65.2, 67.1, 105.2, 125.7, 128.2, 130.0, 133.6, 137.27, 137.29. IR (neat) 3357, 1436, 1389, 1253, 1051 cm⁻¹. MS (APCI)

calcd for $C_{11}H_{12}Br_2ClO_2 [M+H]^+$ 368.8887, found 368.8882.

3. Transformation of 4a into Substituted Furan Derivartives (Scheme 2).

To a solution of **4a** (2.77 g, 8.62 mmol) in MeOH (40 mL) was added conc. H₂SO₄ (91.7 μ L, 1.72 mmol) at 0 °C and the reaction mixture was stirred at room temperature for 1 h. Saturated NaHCO₃ aqueous solution (30 mL) was added to the mixture, and volatile solvents were removed under reduced pressure. The residue was extracted with AcOEt (30 mL × 3), and then the organic phase was washed with brine (50 mL) and dried over Na₂SO₄. The organic phase concentrated under reduced pressure, and the crude products was purified by column chromatography (eluent: hexane/AcOEt=30:1) to give the desired product **9** (2.67 g, 92% yield).



3,3-Dibromo-2-methoxy-2-phenyltetrahydrofuran (9): ¹H NMR (400 MHz, CDCl₃) δ 3.08 (ddd, J = 13.5, 7.3, 2.1 Hz, 1H), 3.12 (s, 3H), 3.45 (dt, J = 13.5, 9.6 Hz, 1H), 4.00-4.08 (m, 1H), 4.26-4.35 (m, 1H), 7.38-7.44 (m, 3H), 7.72-7.78 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 47.1, 51.4, 64.8, 67.9, 108.4, 127.5 (2C), 128.3, 129.1 (2C), 134.7. IR (neat) 2935, 1449, 1273, 1117, 1040 cm⁻¹. MS (APCI) calcd for C₁₁H₁₂Br₂O₂ [M+H]⁺ 333.9199, found 333.9199.

To a solution of **9** (67.2 mg, 0.20 mmol) in THF (1.25 mL) was added *t*-BuOK (33.7 mg, 0.30 mmol) in THF (0.50 mL) at room temperature. The reaction mixture was stirred at 80 °C for 3 h. Saturated NH₄Cl aqueous solution (10 mL) was added to the mixture, and the product was extracted with AcOEt (10 mL \times 3). The organic phase was washed with brine (20 mL) and dried over Na₂SO₄. The organic phase concentrated under reduced pressure. The pure product **10** was gave without further purification (47.3 mg, 98% yield).



3-Bromo-2-methoxy-2-phenyl-2,5-dihydrofuran (10): ¹H NMR (400 MHz, CDCl₃) δ 3.34 (s, 3H), 4.78 (d, J = 1.8 Hz, 2H), 6.41 (t, J = 1.8 Hz, 1H), 7.31-7.39 (m, 3H), 7.50-7.56 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 49.7, 74.7, 112.8, 119.5, 126.4 (2C), 127.9 (2C), 128.6, 130.2, 139.7. IR (neat) 2928, 1449, 1270, 1190, 1044 cm⁻¹. MS (APCI) calcd for C₁₁H₁₂BrO₂ [M+H]⁺ 255.0015, found 255.0017.

To a solution of **10** (47.3 mg, 0.20 mmol) in MeCN (1.7 mL) was added *p*-TsOH•H₂O (38.0 mg, 0.20 mmol) at room temperature. The reaction mixture was stirred at room temperature for 30 min. Saturated NaHCO₃ aqueous solution (10 mL) was added to the mixture, and the product was extracted with AcOEt (10mL × 3). The organic phase was washed with brine (20 mL) and dried over Na₂SO₄. The organic phase concentrated under reduced pressure, and the crude products was purified by column chromatography (eluent: hexane/AcOEt=50:1) to give the desired product **11** (43.5 mg, >99% yield).



3-Bromo-2-phenylfuran (11): ¹H NMR (400 MHz, CDCl₃) δ 6.53 (d, J = 2.0 Hz, 1H), 7.30-7.36 (m, 1H), 7.39-7.46 (m, 3H), 7.93-7.98 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 95.9, 116.2, 125.5 (2C), 128.0, 128.5 (2C), 129.7, 141.7, 148.9. IR (neat) 3057, 1480, 1373, 1186, 1056 cm⁻¹. MS (APCI) calcd for C₁₀H₈BrO [M+H]⁺ 222.9753, found 222.9752.

To a solution of **9** (67.2 mg, 0.20 mmol) in CH₂Cl₂ (0.40 mL) was added allyltrimethylsilane (63.8 μ L, 0.40 mmol) and BF₃-OEt₂ (50.5 μ L, 0.20 mmol) at -78 °C under argon atmosphere, and the reaction mixture stirred at room temperature for 16 h. Saturated NaHCO₃ aqueous solution (10 mL) was added to the mixture, and the product was extracted with AcOEt (10mL × 3). The organic phase was washed with brine (20 mL) and dried over Na₂SO₄. The organic phase concentrated under reduced pressure, and the crude products was purified by column chromatography (eluent: hexane/AcOEt =50:1) to give the desired product **12** (62.7 mg, 92% yield).



2-Allyl-3,3-dibromo-2-phenyltetrahydrofuran (12): ¹H NMR (400 MHz, CDCl₃) δ 2.65 (dd, *J* = 14.6, 7.4 Hz, 1H), 3.12-3.37 (m, 3H), 4.10 (td, *J* = 9.2, 3.2 Hz, 1H), 4.24-4.33 (m, 1H), 4.92-5.03 (m, 2H), 5.39-5.52 (m, 1H), 7.29-7.40 (m, 3H), 7.63-7.69 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 43.0, 49.2, 64.1, 70.7, 90.9, 118.3, 125.9 (2C), 127.6 (2C), 127.7, 133.3, 141.3. IR (neat) 2892, 1640, 1447, 1270, 1063 cm⁻¹. MS (APCI) calcd for C₁₃H₁₅Br₂O [M+H]⁺ 344.9484, found 344.9491.

To a solution of **12** (58.5 mg, 0.17 mmol) in Et₂O (0.42 mL) was added MeLi (250 μ L, 0.25 mmol) dropwise at -78 °C under argon atmosphere, and the reaction mixture was stirred at same temperature for 4 h. H₂O (10 mL) was added to the mixture, and the product was extracted with Et₂O (10mL × 3). The organic phase was washed with brine (20 mL) and dried over Na₂SO₄. The organic phase concentrated under reduced pressure, and the crude products was purified by column chromatography (eluent: hexane/Et₂O =30:1) to give the desired product **13** (28.5 mg, 91% yield).



2-Allyl-2-phenyl-2,5-dihydrofuran (13): ¹H NMR (400 MHz, CDCl₃) δ 2.66 (dd, J = 14.4, 7.5 Hz, 1H), 2.71 (dd, J = 14.4, 6.8 Hz, 1H), 4.68-4.80 (m, 2H), 5.01-5.11 (m, 2H), 5.67-5.80 (m, 1H), 5.91 (dt, J = 6.2, 1.6 Hz, 1H), 6.01 (dt, J = 6.2, 2.5 Hz, 1H), 7.20-7.26 (m, 1H), 7.30-7.36 (m, 2H), 7.36-7.41 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 46.0, 75.3, 93.0, 117.7, 124.9 (2C), 126.0, 126.8, 128.2 (2C), 132.2, 133.7, 145.4. IR (neat) 2848, 1640, 1446, 1261, 1057 cm⁻¹. MS (APCI) calcd for C₁₃H₁₅O [M+H]⁺ 187.1117, found 187.1116.

To a solution of **12** (86.5 mg, 0.25 mmol) in THF (1.7 mL) was added *t*-BuOK (42.1 mg, 0.375 mmol) at room temperature, and the reaction mixture was stirred at 80 °C for 2 h. Saturated NH₄Cl aqueous solution (10 mL) was added to the mixture, and the product was extracted with Et₂O (10mL × 3). The organic phase was washed with brine (20 mL) and dried over Na₂SO₄. The organic phase concentrated under reduced pressure, and the crude products was purified by column chromatography (eluent: hexane/Et₂O =50:1) to give the desired product **14** (63.3 mg, 96% yield).



2-Allyl-3-bromo-2-phenyl-2,5-dihydrofuran (14): ¹H NMR (400 MHz, CDCl₃) δ 2.81 (dd, *J* = 14.6, 6.6 Hz, 1H), 2.91 (dd, *J* = 14.6, 7.3 Hz, 1H), 4.68 (dd, *J* = 13.0, 1.8 Hz, 1H), 4.77 (dd, *J* = 13.0, 1.8 Hz, 1H), 5.09-5.16 (m, 1H), 5.17-5.25 (m, 1H), 5.75-5.88 (m, 1H), 6.05 (t, *J* = 1.8 Hz, 1H), 7.25-7.32 (m, 1H), 7.32-7.39 (m, 2H), 7.47-7.54 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ

41.7, 74.8, 92.7, 118.7, 122.8, 125.8 (2C), 126.5, 127.6, 128.1 (2C), 132.6, 142.5. IR (neat) 2850, 1628, 1446, 1342, 1209, 1065 cm⁻¹. MS (APCI) calcd for $C_{13}H_{14}BrO [M+H]^+$ 265.0223, found 265.0218.

To a solution of **14** (53.0 mg, 0.20 mmol) and silica gel (129.9 mg) in CH_2Cl_2 (1.2 mL) was added PCC (129.9 mg, 0.60 mmol) under argon atmosphere, and the reaction mixture was stirred at 40 °C for 21 h. To the solution was added PCC (43.3 mg, 0.20 mmol), and then the reaction mixture was stirred at 40 °C for 9 h. The mixture was filtered through Celite[®] and washed with a mixture of CH₂Cl₂ and Et₂O (1/4) (10 mL × 3). The filtrate was washed with brine (20 mL) and dried over Na₂SO₄. The organic phase concentrated under reduced pressure, and the crude products was purified by column chromatography (eluent: hexane/AcOEt =10:1) to give the desired product **15** (44.7 mg, 80% yield).



5-Allyl-4-bromo-5-phenylfuran-2(5*H***)-one (15):** ¹H NMR (400 MHz, CDCl₃) δ 3.02 (dd, J = 14.8, 7.6 Hz, 1H), 3.09 (dd, J = 14.8, 6.8 Hz, 1H), 5.17-5.32 (m, 2H), 5.58-5.72 (m, 1H), 6.29 (s, 1H), 7.35-7.48 (m, 5H). ¹³C NMR (100 MHz, CDCl₃) δ 39.7, 91.7, 121.3, 121.6, 125.5 (2C), 128.7 (2C), 129.0, 129.1, 136.0, 154.8, 169.9. IR (neat) 2926, 1745, 1600, 1447, 1251, 1193 cm⁻¹. MS (APCI) calcd for C₁₃H₁₂BrO₂ [M+H]⁺ 279.0015, found 279.0009.

A solution of **14** (53.0 mg, 0.20 mmol), PhB(OH)₂ (61.0 mg, 0.50 mmol), and PdCl₂(PPh₃)₂ (14.0 mg, 0.020 mmol) in DMF (4.0 mL) was stirred at room temperature for 30 min. 2 M K₂CO₃ aqueous solution (0.80 mL) was added to the reaction mixture, and the mixture was stirred at 60 °C for 4 h. H₂O (10 mL) was added to reaction mixture, and extracted with Et₂O (10 mL × 3). The organic phase was washed with brine (20 mL) and dried over Na₂SO₄. The organic phase concentrated under reduced pressure, and the crude products was purified by column chromatography (eluent: hexane/Et₂O =30:1) to give the desired product **16** (50.4 mg, 96% yield).



2-Allyl-2,3-diphenyl-2,5-dihydrofuran (16): ¹H NMR (400 MHz, CDCl₃) δ 2.92 (ddt, J = 14.4,

7.6, 1.2 Hz, 1H), 3.04 (ddt, J = 14.4, 6.6, 1.2 Hz, 1H), 4.81 (dd, J = 14.0, 2.0 Hz, 1H), 4.91 (dd, J = 14.0, 2.0 Hz, 1H), 4.98-5.07 (m, 2H), 5.87 (m, 1H), 6.22 (t, J = 2.0 Hz, 1H), 7.02-7.07 (m, 2H), 7.15-7.23 (m, 3H), 7.24-7.28 (m, 1H), 7.28-7.36 (m, 2H), 7.39-7.45 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 41.3, 74.6, 93.1, 118.0, 124.3, 126.2 (2C), 127.4 (2C), 127.5, 127.6, 128.1 (2C), 128.3 (2C), 133.6, 133.8, 143.9, 144.3. IR (neat) 2843, 1445, 1205, 1068, 913 cm⁻¹. MS (APCI) calcd for C₁₉H₁₉O [M+H]⁺ 263.1430, found 263.1420.

To a solution of **14** (53.0 mg, 0.20 mmol), Pd(PPh₃)₄ (11.6 mg, 0.05 mmol) in toluene (1.0 mL) was added tributylvinyltin (70.1 μ L, 0.24 mmol) at room temperature, and then the reaction mixture was stirred at 100 °C for 4 h. The reaction mixture was cooled to room temperature and distilled with Et₂O (10 ml). The organic phase was washed with brine (10 mL) and dried over Na₂SO₄. The organic phase concentrated under reduced pressure, and the crude products was purified by column chromatography (eluent: hexane/Et₂O =30:1) to give the desired product **17** (38.0 mg, 90% yield).



2-Allyl-2-phenyl-3-vinyl-2,5-dihydrofuran (17): ¹H NMR (400 MHz, CDCl₃) δ 2.89 (dd, J = 14.4, 7.2 Hz, 1H), 2.97 (dd, J = 14.4, 6.8 Hz, 1H), 4.72 (dq, J = 14.4, 1.2 Hz, 1H), 4.80 (dq, J = 14.4, 1.2 Hz, 1H), 5.04-5.10 (m, 2H), 5.11-5.24 (m, 2H), 5.77-5.90 (m, 1H), 6.02 (s, 1H), 6.22 (ddd, J = 17.8, 11.2, 1.2 Hz, 1H), 7.22-7.28 (m, 1H), 7.30-7.36 (m, 2H), 7.40-7.45 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 41.7, 74.3, 92.3, 117.0, 117.8, 124.8, 125.9 (2C), 127.3, 128.2 (2C), 128.8, 133.6, 142.4, 144.3. IR (neat) 2841, 1446, 1195, 1069, 909 cm⁻¹. MS (APCI) calcd for C₁₅H₁₇O [M+H]⁺ 213.1274, found 213.1266.

4. Mechanistic Studies for Catalytic Dehydrogenative Dual Functionalization of Ethers (1). 4.1. Fluctuation of catalytic dehydrogenative dual functionalization products by amount of aq. HBr (Figure S1).





Figure S1. Plot of percentage yield (%) of products for the DDF of **1a** versus equivalent amount of aq. HBr (equiv.). \Diamond : **1a**. \Box : α -ethyl-benzyl alcohol (**1ab**). \triangle : propiophenone (**14**). \bigcirc : **2a**.

4.2. Reactivity of each reaction by varying amounts of aq. HBr and existence of sulfonamide catalyst (Scheme S1, Eqs S1–S3).



Scheme S1. Mechanistic studies of DDF of ethers via aerobic oxidation of bromide. ^{*a*}Number in brackets indicated yield of 2a. ^{*b*}Number in brackets indicates recovery of 15. ^{*c*}Number in brackets indicates recovery of 14.

4.3. ¹H-NMR titration experiments for *p*-NO₂-C₆H₄SO₂NH₂ with Br₂ in CD₃CN (Figure S2).

NMR tube was charged with p-NO₂-C₆H₄SO₂NH₂ (4.7 mg, 0.023 mmol) in CD₃CN (750 µL) at room temperature. To the solution, Br₂ was added so that the molecular ratio of bromine and p-NO₂-C₆H₄SO₂NH₂ ([Br₂]/[p-NO₂-C₆H₄SO₂NH₂]) becomes 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 10.0, 20.0, and 30.0. All the ¹H-NMR spectra were measured on a JEOL ECS-500 spectrometer and chemical shifts were recorded in ppm from the solvent resonance employed as the internal standard (cyclohexane at 1.44 ppm).



Figure S2. ¹H-NMR data for titration of p-NO₂-C₆H₄SO₂NH₂ with Br₂. Plot of variation of change in chemical shift ($\Delta\delta$) versus [Br₂]/[p-NO₂-C₆H₄SO₂NH₂]: H^a (red \bullet), H^b (green \blacktriangle), H^c (bule \blacksquare), CH₃CN (brack, +).





























